Table 3.
Whole Blood Clinical Chemistry Markers
| 300 mg | 600 mg | |||||||||
| Week | 0 | 1 | 3 | 8 | 11 | 0 | 1 | 3 | 8 | 11 |
| WBC (K/μL) | 5.3 ± 1.6 | 5.0 ± 1.1 | 5.3 ± 1.7 | 5.2 ± 2.0 | 4.5 ± 1.5 | 5.5 ± .96 | 4.6 ± .91 | 5.0 ± 1.0 | 4.9 ± .67 | 5.1 ± .84 |
| RBC (M/μL) | 5.0 ± .51 | 5.0 ± .50 | 4.6 ± .84 | 5.0 ± .37 | 4.9 ± .46 | 5.2 ± .37 | 5.1 ± .33 | 5.2 ± .24 | 4.9 ± 1.2 | 5.3 ± .30 |
| Hemoglobin (g/dL) | 15 ± 1.1 | 15 ± 1.1 | 15 ± 1.2 | 15 ± .59 | 15 ± 1.0 | 15 ± .95 | 15 ± .93 | 15 ± .63 | 15 ± .66 | 15 ± .78 |
| Hematocrit (%) | 44 ± 3.5 | 44 ± 3.7 | 44 ± 3.6 | 45 ± 2.4 | 43 ± 3.3 | 46 ± 3.0* | 44 ± 2.3* | 45 ± 1.9* | 46 ± 2.1* | 46 ± 2.7* |
| MCV (fL) | 88 ± 2.8 | 88 ± 2.8 | 88 ± 2.4 | 89 ± 2.4 | 89 ± 2.9 | 87 ± 2.7 | 86 ± 2.8 | 87 ± 2.6 | 87 ± 2.3 | 87 ± 2.5 |
| MCH (pg) | 30 ± 1.2 | 30 ± 1.3 | 30 ± 1.0 | 30 ± 1.3 | 30 ± 1.0 | 29 ± 1.0 | 29 ± .95 | 29 ± .98 | 29 ± 1.1 | 29 ± .78 |
| MCHC (g/dL) | 34 ± .69 | 34 ± .76 | 34 ± .64 | 33 ± .78 | 34 ± .81 | 33 ± .60 | 34 ± .85 | 33 ± .56 | 33 ± .61 | 34 ± .60 |
| Neutrophils | 2.9 ± 1.0 | 2.5 ± .43 | 2.9 ± 1.1 | 2.8 ± 1.0 | 2.3 ± 1.1 | 2.8 ± .52 | 2.4 ± .47 | 2.6 ± .66 | 2.5 ± .29 | 2.9 ± 1.1 |
| Lymphocytes | 1.7 ± .51 | 1.9 ± .84 | 1.7 ± .62 | 1.8 ± .87 | 1.6 ± .69 | 2.0 ± .39 | 1.6 ± .39 | 1.8 ± .50 | 1.7 ± .44 | 1.8 ± .44 |
| Monocytes | .45 ± .12 | .39 ± .12 | .44 ± .12 | .36 ± .07 | .37 ± .14 | .43 ± .14* | .38 ± .04* | .39 ± .13* | .40 ± .09* | .44 ± .12* |
| Eosinophils | .12 ± .06 | .13 ± .08 | .11 ± .05 | .12 ± .06 | .12 ± .06 | .14 ± .08 | .14 ± .09 | .16 ± .10 | .16 ± .09 | .16 ± .07 |
| Basophils | .06 ± .02 | .05 ± .01 | .05 ± .01 | .05 ± .01 | .05 ± .02 | .07 ± .02* | .06 ± .02* | .07 ± .02* | .07 ± .01* | .06 ± .01* |
* Denotes significant main effects for groups (p < 0.05) indicating that the 600 mg group had higher baselines values that persisted throughout the study, and was apparently independent of 6-OXO supplementation.